Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Corcept Therapeutics Incorporated or Haleon plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Corcept Therapeutics Incorporated and Haleon plc compare based on key financial metrics to determine which better meets your investment needs.

About Corcept Therapeutics Incorporated and Haleon plc

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Latest Pharmaceuticals and Corcept Therapeutics Incorporated, Haleon plc Stock News

As of July 31, 2026, Corcept Therapeutics Incorporated had a $12.4 billion market capitalization, compared to the Pharmaceuticals median of $579.1 million. Corcept Therapeutics Incorporated’s stock is up 229% in 2026, up 20.1% in the previous five trading days and up 63.77% in the past year.

Currently, Corcept Therapeutics Incorporated’s price-earnings ratio is 252.2. Corcept Therapeutics Incorporated’s trailing 12-month revenue is $830.8 million with a 6.6% net profit margin. Year-over-year quarterly sales growth most recently was 31.7%. Analysts expect adjusted earnings to reach $2.280 per share for the current fiscal year. Corcept Therapeutics Incorporated does not currently pay a dividend.

As of July 31, 2026, Haleon plc had a $43.0 billion market cap, putting it in the 92nd percentile of all stocks. Haleon plc’s stock is down 2.4% in 2026, up 0.9% in the previous five trading days and up 2.39% in the past year.

Currently, Haleon plc’s price-earnings ratio is 41.1. Haleon plc’s trailing 12-month revenue is $14.8 billion with a 14.6% net profit margin. Year-over-year quarterly sales growth most recently was -1.0%. There are no analysts providing consensus earnings estimates for the current fiscal year. Haleon plc currently has a 2.7% dividend yield.

How We Compare Corcept Therapeutics Incorporated and Haleon plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Corcept Therapeutics Incorporated and Haleon plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Corcept Therapeutics Incorporated and Haleon plc Stock Value Grades

Company	Ticker	Value
Corcept Therapeutics Incorporated	CORT	F
Haleon plc	HLN	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Corcept Therapeutics Incorporated has a Value Score of 3, which is Ultra Expensive. Haleon plc has a Value Score of 23, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Corcept Therapeutics Incorporated or Haleon plc has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Corcept Therapeutics Incorporated or Haleon plc is the better investment when it comes to value.

Corcept Therapeutics Incorporated and Haleon plc Growth Grades

Company	Ticker	Growth
Corcept Therapeutics Incorporated	CORT	A
Haleon plc	HLN	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Corcept Therapeutics Incorporated has a Growth Score of 89, which is Very Strong. Haleon plc has a Growth Score of 56, which is Average.

The Growth Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Growth Grade breakdown above, Corcept Therapeutics Incorporated has a more attractive growth grade than Haleon plc. For investors who focus solely on how a company is growing relative to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Corcept Therapeutics Incorporated and Haleon plc’s Momentum Grades

Company	Ticker	Momentum
Corcept Therapeutics Incorporated	CORT	A
Haleon plc	HLN	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Corcept Therapeutics Incorporated has a Momentum Score of 98, which is Very Strong. Haleon plc has a Momentum Score of 47, which is Average.

The Momentum Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Momentum Grade breakdown above, Corcept Therapeutics Incorporated is considered to have stronger momentum compared to Haleon plc. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Corcept Therapeutics Incorporated and Haleon plc Grades

In addition to Value, Growth and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Corcept Therapeutics Incorporated and Haleon plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Corcept Therapeutics Incorporated or Haleon plc Stock?

Overall, Corcept Therapeutics Incorporated stock has a Value Score of 3, Growth Score of 89 and Momentum Score of 98.

Haleon plc stock has a Value Score of 23, Growth Score of 56 and Momentum Score of 47.

Comparing Corcept Therapeutics Incorporated and Haleon plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.